Shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) ended Monday session in green amid volatile trading. The shares closed up +0.005 points or 2.86% at $0.162 with 116,056.00 shares getting traded. Post opening the session at $0.16, the shares hit an intraday low of $0.16 and an intraday high of $0.17 and the price vacillated in this range throughout the day. The company has a market cap of $3.95 million and the numbers of outstanding shares have been calculated to be 24.77 million shares.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Shares of Baxter International Inc (NYSE:BAX) ended Monday session in green amid volatile trading. The shares closed up +0.05 points or 0.11% at $47.64 with 2.60 million shares getting traded. Post opening the session at $47.30, the shares hit an intraday low of $47.04 and an intraday high of $47.68 and the price vacillated in this range throughout the day. The company has a market cap of $26.29 billion and the numbers of outstanding shares have been calculated to be 543.89 million shares.
Baxter International Inc (BAX) has been recognized by Thomson Reuters as a Top 100 company for outstanding practices in diversity and inclusion in its inaugural Diversity & Inclusion Index, which debuted. The index and ratings are designed to transparently and objectively measure the relative performance of companies against factors that define sustainable, diverse and inclusive workplaces.
”Baxter is committed to fostering an inclusive work environment that attracts, engages and retains a diverse workforce to drive healthcare innovation that betters the lives of the patients we serve,” said Baxter Chairman and Chief Executive Officer José (Joe) Almeida. ”Integrating different backgrounds and perspectives within all facets of our organization is what allows us to continue delivering on our mission to save and sustain lives.”